Why the study?
Due to multiple organ involvement and constant inflammation, systemic sclerosis patients have an increased risk of infectious diseases, warranting gathered up-to-date evidence on vaccination strategies.
What is the up-to-date evidence on the safety, immunogenicity, and efficacy of vaccination strategies for patients with systemic sclerosis?
What is the up-to-date evidence on the safety, immunogenicity, and efficacy of vaccination strategies for patients with systemic sclerosis?
This scoping review summarizes current evidence on the safety, immunogenicity, and efficacy of various vaccines to aid in the prevention and management of infectious diseases in patients with systemic sclerosis.
Answers are grounded in this paper and cite their sources.
May guide current SSc vaccination to cut infection risk; leaves open dedicated trials on immunogenicity under immunosuppression.
Systemic sclerosis (SSc) is a rare autoimmune inflammatory rheumatic disease. The prevalence of SSc ranges from 7 to 700 cases per million worldwide. Due to multiple organ involvement and constant inflammatory state, this group of patients presents an increased risk of infectious diseases. This paper aimed to gather the up-to-date evidence on vaccination strategies for patients with SSc and to be a useful tool for the prevention and management of infectious diseases. The authors conducted a scoping review in which each paragraph presents data on a specific vaccine’s safety, immunogenicity, and efficacy. The work deals with the following topics: SARS-CoV-2, seasonal influenza, S. pneumoniae, HAV, HBV, HZV, N. meningitidis, H. influenzae, HPV, and diphtheria-tetanus-pertussis.
No takes yet. Share an insight, caveat, or question.
Murdaca et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: